Drugs / MT-6548
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03645863 | Aug → Sep 2018 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03461146 | Mar → Dec 2018 | anemia | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03439137 | Feb → Dec 2018 | anemia due to chronic disorder | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 3 | NCT03402386 | Jan → Nov 2018 | anemia due to chronic disorder | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03329196 | Oct 2017 → Jan 2019 | anemia | Tanabe Pharma Corporation | Completed | Met primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-11 | Tanabe Pharma Corporation | HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 tanabe-pharma.com ↗ |
| 2019-10-25 | Tanabe Pharma Corporation | Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019 tanabe-pharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-6548 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03645863 ↗ |